LYZ and soft tissue sarcoma: More recently, bioinformatic studies investigating the immune signatures of melanoma, laryngeal squamous cell carcinoma, glioblastoma, and soft tissue sarcomas have indicated that the messenger RNA level of LYZ can act as an immune-related marker for predicting prognosis or response to immune therapies in these tumors [12,13].